Pro- or anti-inflammatory properties of cytokines in COVID-19: which offer better protection against disease?
作者信息
Jadali Z
机构信息
Tehran University of Medical Sciences.
出版信息
Arch Razi Inst. 2024 Apr 30;79(2):246-247. doi: 10.32592/ARI.2024.79.2.246. eCollection 2024 Apr.
Abstract
摘要
相似文献
1
Pro- or anti-inflammatory properties of cytokines in COVID-19: which offer better protection against disease?细胞因子在新冠病毒疾病中的促炎或抗炎特性：哪种特性能更好地抵御疾病？
Arch Razi Inst. 2024 Apr 30;79(2):246-247. doi: 10.32592/ARI.2024.79.2.246. eCollection 2024 Apr.
2
Serum profiles of pro-inflammatory and anti-inflammatory cytokines in non-hospitalized patients with mild/moderate COVID-19 infection.非住院轻/中度 COVID-19 感染患者的促炎和抗炎细胞因子的血清谱。
Immunol Lett. 2023 Aug;260:24-34. doi: 10.1016/j.imlet.2023.06.008. Epub 2023 Jun 18.
3
SARS-CoV-2, which induces COVID-19, causes kawasaki-like disease in children: role of pro-inflammatory and anti-inflammatory cytokines.引起 COVID-19 的 SARS-CoV-2 可导致儿童川崎病：促炎和抗炎细胞因子的作用。
J Biol Regul Homeost Agents. 2020;34(3):767-773. doi: 10.23812/EDITORIAL-RONCONI-E-59.
4
Mechanisms of Immunomodulation and Cytoprotection Conferred to Pancreatic Islet by Human Amniotic Epithelial Cells.人羊膜上皮细胞赋予胰岛免疫调节和细胞保护的机制。
Stem Cell Rev Rep. 2022 Jan;18(1):346-359. doi: 10.1007/s12015-021-10269-w. Epub 2021 Oct 6.
5
Prediction and identification of T cell epitopes of COVID-19 with balanced cytokine response for the development of peptide based vaccines.预测和鉴定新冠病毒具有平衡细胞因子反应的T细胞表位，用于开发基于肽的疫苗。
In Silico Pharmacol. 2021 Jun 28;9(1):40. doi: 10.1007/s40203-021-00098-7. eCollection 2021.
6
Dynamic shifts in lung cytokine patterns in post-COVID-19 interstitial lung disease patients: a pilot study.新冠后间质性肺疾病患者肺部细胞因子模式的动态变化：一项初步研究。
Ther Adv Chronic Dis. 2024 Mar 30;15:20406223241236257. doi: 10.1177/20406223241236257. eCollection 2024.
7
Cytokines in Pain: Harnessing Endogenous Anti-Inflammatory Signaling for Improved Pain Management.细胞因子与疼痛：内源性抗炎信号的利用以改善疼痛管理。
Front Immunol. 2019 Dec 23;10:3009. doi: 10.3389/fimmu.2019.03009. eCollection 2019.
8
Antiviral and anti-inflammatory drugs to combat COVID-19: Effects on cardiac ion channels and risk of ventricular arrhythmias.对抗新冠病毒的抗病毒和抗炎药物：对心脏离子通道的影响及室性心律失常风险
Bioimpacts. 2022;12(1):9-20. doi: 10.34172/bi.2021.23630. Epub 2021 Dec 22.
9
Colchicine in the management of Covid-19: With or lieu of evidence.秋水仙碱在治疗 COVID-19 中的应用：有或无证据支持。
J Pak Med Assoc. 2021 Dec;71(Suppl 8)(12):S127-S132.
10
The crucial role of prolactin-lactogenic hormone in Covid-19.催乳素-生乳激素在新冠病毒中的关键作用。
Mol Cell Biochem. 2022 May;477(5):1381-1392. doi: 10.1007/s11010-022-04381-9. Epub 2022 Feb 11.
本文引用的文献
1
Evaluation of IL-6, IL-25 & IL-35 in the COVID 19 Patients and their Correlation to Demography Data in the Symptomatic Patients.评估 COVID-19 患者的 IL-6、IL-25 和 IL-35 及其与症状患者人口统计学数据的相关性。
Arch Razi Inst. 2023 Jun 30;78(3):1049-1056. doi: 10.22092/ARI.2022.360087.2547. eCollection 2023 Jun.
2
Emerging aspects of cytokine storm in COVID-19: The role of proinflammatory cytokines and therapeutic prospects.新型冠状病毒病中细胞因子风暴的新方面：促炎细胞因子的作用和治疗前景。
Cytokine. 2023 Sep;169:156287. doi: 10.1016/j.cyto.2023.156287. Epub 2023 Jun 26.
3
Increased Pro Th1 And Th17 Transcriptional Activity In Patients With Severe COVID-19.重症 COVID-19 患者 Th1 和 Th17 转录活性增加。
Int J Med Sci. 2023 Feb 21;20(4):530-541. doi: 10.7150/ijms.80498. eCollection 2023.
4
Immunotherapy of COVID-19: Inside and Beyond IL-6 Signalling.COVID-19 的免疫疗法：IL-6 信号通路内外
Front Immunol. 2022 Feb 22;13:795315. doi: 10.3389/fimmu.2022.795315. eCollection 2022.
5
The anti-inflammatory cytokine response characterized by elevated interleukin-10 is a stronger predictor of severe disease and poor outcomes than the pro-inflammatory cytokine response in coronavirus disease 2019 (COVID-19).在 2019 冠状病毒病（COVID-19）中，以白细胞介素-10 升高为特征的抗炎细胞因子反应比促炎细胞因子反应更能预测严重疾病和不良结局。
Clin Chem Lab Med. 2020 Nov 26;59(3):599-607. doi: 10.1515/cclm-2020-1284. Print 2021 Feb 23.
Zotero 插件